Cargando…
Compound heterozygous loss of function variants in MYL9 in a child with megacystis–microcolon–intestinal hypoperistalsis syndrome
Megacystis–microcolon–intestinal hypoperistalsis syndrome (MMIHS), or “visceral myopathy,” is a severe early onset disorder characterized by impaired muscle contractility in the bladder and intestines. Five genes are linked to MMIHS: primarily ACTG2, but also LMOD1, MYH11, MYLK, and MYL9. Here we de...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667357/ https://www.ncbi.nlm.nih.gov/pubmed/33031641 http://dx.doi.org/10.1002/mgg3.1516 |
_version_ | 1783610296164679680 |
---|---|
author | Kandler, Justin L. Sklirou, Evgenia Woerner, Audrey Walsh, Leslie Cox, Eleina Xue, Yuan |
author_facet | Kandler, Justin L. Sklirou, Evgenia Woerner, Audrey Walsh, Leslie Cox, Eleina Xue, Yuan |
author_sort | Kandler, Justin L. |
collection | PubMed |
description | Megacystis–microcolon–intestinal hypoperistalsis syndrome (MMIHS), or “visceral myopathy,” is a severe early onset disorder characterized by impaired muscle contractility in the bladder and intestines. Five genes are linked to MMIHS: primarily ACTG2, but also LMOD1, MYH11, MYLK, and MYL9. Here we describe a three‐year‐old girl with bilateral hydronephrosis diagnosed at 20 weeks gestation and congenital mydriasis (both of which have been previously observed among individuals with MMIHS). A clinical diagnosis of MMIHS was made based upon the presence of megacystis, lack of urinary bladder peristalsis, and intestinal pseudo‐obstruction. After initial testing of ACTG2 was negative, further sequencing and deletion/duplication testing was performed on the LMOD1, MYH11,MYLK, and MYL9 genes. We identified two heterozygous loss of function variants in MYL9: an exon 4 deletion and a nine base pair deletion that removes the canonical splicing donor site at exon 2 (NM_006097.5:c.184+2_184+10del). Parental testing confirmed these variants to be in trans in our proband. To our knowledge, only one other individual with MMIHS has biallelic mutations in MYL9 (a homozygous deletion encompassing exon 4). We suggest MYL9 be targeted on genetic testing panels for MMIHS, smooth muscle myopathies, and cardiovascular phenotypes. |
format | Online Article Text |
id | pubmed-7667357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76673572020-11-20 Compound heterozygous loss of function variants in MYL9 in a child with megacystis–microcolon–intestinal hypoperistalsis syndrome Kandler, Justin L. Sklirou, Evgenia Woerner, Audrey Walsh, Leslie Cox, Eleina Xue, Yuan Mol Genet Genomic Med Clinical Reports Megacystis–microcolon–intestinal hypoperistalsis syndrome (MMIHS), or “visceral myopathy,” is a severe early onset disorder characterized by impaired muscle contractility in the bladder and intestines. Five genes are linked to MMIHS: primarily ACTG2, but also LMOD1, MYH11, MYLK, and MYL9. Here we describe a three‐year‐old girl with bilateral hydronephrosis diagnosed at 20 weeks gestation and congenital mydriasis (both of which have been previously observed among individuals with MMIHS). A clinical diagnosis of MMIHS was made based upon the presence of megacystis, lack of urinary bladder peristalsis, and intestinal pseudo‐obstruction. After initial testing of ACTG2 was negative, further sequencing and deletion/duplication testing was performed on the LMOD1, MYH11,MYLK, and MYL9 genes. We identified two heterozygous loss of function variants in MYL9: an exon 4 deletion and a nine base pair deletion that removes the canonical splicing donor site at exon 2 (NM_006097.5:c.184+2_184+10del). Parental testing confirmed these variants to be in trans in our proband. To our knowledge, only one other individual with MMIHS has biallelic mutations in MYL9 (a homozygous deletion encompassing exon 4). We suggest MYL9 be targeted on genetic testing panels for MMIHS, smooth muscle myopathies, and cardiovascular phenotypes. John Wiley and Sons Inc. 2020-10-08 /pmc/articles/PMC7667357/ /pubmed/33031641 http://dx.doi.org/10.1002/mgg3.1516 Text en © 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Reports Kandler, Justin L. Sklirou, Evgenia Woerner, Audrey Walsh, Leslie Cox, Eleina Xue, Yuan Compound heterozygous loss of function variants in MYL9 in a child with megacystis–microcolon–intestinal hypoperistalsis syndrome |
title | Compound heterozygous loss of function variants in MYL9 in a child with megacystis–microcolon–intestinal hypoperistalsis syndrome |
title_full | Compound heterozygous loss of function variants in MYL9 in a child with megacystis–microcolon–intestinal hypoperistalsis syndrome |
title_fullStr | Compound heterozygous loss of function variants in MYL9 in a child with megacystis–microcolon–intestinal hypoperistalsis syndrome |
title_full_unstemmed | Compound heterozygous loss of function variants in MYL9 in a child with megacystis–microcolon–intestinal hypoperistalsis syndrome |
title_short | Compound heterozygous loss of function variants in MYL9 in a child with megacystis–microcolon–intestinal hypoperistalsis syndrome |
title_sort | compound heterozygous loss of function variants in myl9 in a child with megacystis–microcolon–intestinal hypoperistalsis syndrome |
topic | Clinical Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667357/ https://www.ncbi.nlm.nih.gov/pubmed/33031641 http://dx.doi.org/10.1002/mgg3.1516 |
work_keys_str_mv | AT kandlerjustinl compoundheterozygouslossoffunctionvariantsinmyl9inachildwithmegacystismicrocolonintestinalhypoperistalsissyndrome AT sklirouevgenia compoundheterozygouslossoffunctionvariantsinmyl9inachildwithmegacystismicrocolonintestinalhypoperistalsissyndrome AT woerneraudrey compoundheterozygouslossoffunctionvariantsinmyl9inachildwithmegacystismicrocolonintestinalhypoperistalsissyndrome AT walshleslie compoundheterozygouslossoffunctionvariantsinmyl9inachildwithmegacystismicrocolonintestinalhypoperistalsissyndrome AT coxeleina compoundheterozygouslossoffunctionvariantsinmyl9inachildwithmegacystismicrocolonintestinalhypoperistalsissyndrome AT xueyuan compoundheterozygouslossoffunctionvariantsinmyl9inachildwithmegacystismicrocolonintestinalhypoperistalsissyndrome |